Joanna Baran

Mrs. Joanna Baran

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AMAnna Mazurkiewicz-Pisarek
Anna Mazurkiewicz-Pisarek
JBJoanna Baran
Joanna Baran
TCTomasz Ciach
Tomasz Ciach
Antimicrobial peptides (AMPs), or host defence peptides, are short proteins in various life forms. Here we discuss AMPs, which may become a promising substitute or adjuvant in pharmaceutical, biomedical, and cosmeceutical uses. Their pharmacological potential has been investigated intensively, especially as antibacterial and antifungal drugs and as promising antiviral and anticancer agents. AMPs exhibit many properties, and some of these have attracted the attention of the cosmetic industry. AMPs are being developed as novel antibiotics to combat multidrug-resistant pathogens and as potential treatments for various diseases, including cancer, inflammatory disorders, and viral infections. In biomedicine, AMPs are being developed as wound-healing agents because they promote cell growth and tissue repair. The immunomodulatory effects of AMPs could be helpful in the treatment of autoimmune diseases. In the cosmeceutical industry, AMPs are being investigated as potential ingredients in skincare products due to their antioxidant properties (anti-ageing effects) and antibacterial activity, which allows the killing of bacteria that contribute to acne and other skin conditions. The promising benefits of AMPs make them a thrilling area of research, and studies are underway to overcome obstacles and fully harness their therapeutic potential. This review presents the structure, mechanisms of action, possible applications, production methods, and market for AMPs.

23 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
AGAleksander Gryciuk
Aleksander Gryciuk
MRMarta Rogalska
Marta Rogalska
JBJoanna Baran
Joanna Baran
Lukasz Kuryk, DSc, MBALukasz Kuryk, DSc, MBA
Lukasz Kuryk, DSc, MBA
MSMonika Staniszewska
Monika Staniszewska
In clinical trials, adenovirus vectors (AdVs) are commonly used platforms for human gene delivery therapy. High genome capacity and flexibility in gene organization make HAdVs suitable for cloning. Recent advancements in molecular techniques have influenced the development of genetically engineered adenovirus vectors showing therapeutic potential. Increased molecular understanding of the benefits and limitations of HAdVs in preclinical research and clinical studies is a crucial point in the engineering of refined oncolytic vectors. This review presents HAdV species (A–G) used in oncotherapy. We describe the adenovirus genome organizations and modifications, the possibilities oncolytic viruses offer, and their current limitations. Ongoing and ended clinical trials based on oncolytic adenoviruses are presented. This review provides a broad overview of the current knowledge of oncolytic therapy. HAdV-based strategies targeting tumors by employing variable immune modifiers or delivering immune stimulatory factors are of great promise in the field of immune oncologyy This approach can change the face of the fight against cancer, supplying the medical tools to defeat tumors more selectively and safely.

1 December 2020 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
MGMałgorzata Gizińska
Małgorzata Gizińska
ASAnna Staniszewska
Anna Staniszewska
MKMichalina Kazek
Michalina Kazek
MKMirosława Koronkiewicz
Mirosława Koronkiewicz
Lukasz Kuryk, DSc, MBALukasz Kuryk, DSc, MBA
Lukasz Kuryk, DSc, MBA
MSMonika Staniszewska
Monika Staniszewska